291 related articles for article (PubMed ID: 9708225)
1. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
Pitt P; Li F; Todd P; Webber D; Pack S; Moniz C
Thorax; 1998 May; 53(5):351-6. PubMed ID: 9708225
[TBL] [Abstract][Full Text] [Related]
2. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
Lems WF; Jacobs JW; Bijlsma JW; van Veen GJ; Houben HH; Haanen HC; Gerrits MI; van Rijn HJ
Ann Rheum Dis; 1997 Jun; 56(6):357-63. PubMed ID: 9227164
[TBL] [Abstract][Full Text] [Related]
3. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
4. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
6. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
[TBL] [Abstract][Full Text] [Related]
7. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.
Campbell IA; Douglas JG; Francis RM; Prescott RJ; Reid DM;
Thorax; 2004 Sep; 59(9):761-8. PubMed ID: 15333852
[TBL] [Abstract][Full Text] [Related]
8. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
[TBL] [Abstract][Full Text] [Related]
9. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
10. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.
Zamberlan N; Castello R; Gatti D; Rossini M; Braga V; Fracassi E; Adami S
Osteoporos Int; 1997; 7(2):133-7. PubMed ID: 9166393
[TBL] [Abstract][Full Text] [Related]
11. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
12. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
[TBL] [Abstract][Full Text] [Related]
15. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
[TBL] [Abstract][Full Text] [Related]
16. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
17. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
[TBL] [Abstract][Full Text] [Related]
18. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
19. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Siffledeen JS; Fedorak RN; Siminoski K; Jen H; Vaudan E; Abraham N; Steinhart H; Greenberg G
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):122-32. PubMed ID: 15704046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]